Mateusz Śpiewak , 1 , Mariusz Kłopotowski 2 , Monika Gawor 3 , Agata Kubik 1 , Ewa Kowalik 4 , Barbara Miłosz-Wieczorek 1 , Maciej Dąbrowski 2 , Konrad Werys 5 , Łukasz Mazurkiewicz 3 , Katarzyna Kożuch 4 , Magdalena Polańska-Skrzypczyk 3 , Joanna Petryka-Mazurkiewicz 1 , 6 , Anna Klisiewicz 4 , Zofia T. Bilińska 7 , Jacek Grzybowski 3 , Adam Witkowski 2 , Magdalena Marczak 1
21 December 2017
Cardiovascular magnetic resonance (CMR) imaging in patients with hypertrophic cardiomyopathy (HCM) enables the assessment of not only left ventricular (LV) hypertrophy and scarring but also the severity of mitral regurgitation. CMR assessment of mitral regurgitation is primarily based on the difference between LV stroke volume (LVSV) and aortic forward flow (Ao) measured using the phase-contrast (PC) technique. However, LV outflow tract (LVOT) obstruction causing turbulent, non-laminar flow in the ascending aorta may impact the accuracy of aortic flow quantification, leading to false conclusions regarding mitral regurgitation severity. Thus, we decided to quantify mitral regurgitation in patients with HCM using Ao or, alternatively, main pulmonary artery forward flow (MPA) for mitral regurgitation volume (MRvol) calculations.
The analysis included 143 prospectively recruited subjects with HCM and 15 controls. MRvol was calculated as the difference between LVSV computed with either the inclusion (LVSV incl) or exclusion (LVSV excl) of papillary muscles and trabeculations from the blood pool and either Ao (MRvol Aoi or MRvol Aoe) or MPA (MRvol MPAi or MRvol MPAe). The presence or absence of LVOT obstruction was determined based on Doppler echocardiography findings.
MRvol Aoi was higher than MRvol MPAi in HCM patients with LVOT obstruction [47.0 ml, interquartile range (IQR) = 31.5–60.0 vs. 35.5 ml, IQR = 26.0–51.0; p < 0.0001] but not in non-obstructive HCM patients (23.0 ml, IQR = 16.0–32.0 vs. 24.0 ml, IQR = 15.3–32.0; p = 0.26) or controls (18.0 ml, IQR = 14.3–21.8 vs. 20.0 ml, IQR = 14.3–22.0; p = 0.89). In contrast to controls and HCM patients without LVOT obstruction, in HCM patients with LVOT obstruction, aortic flow-based MRvol (MRvol Aoi) was higher than pulmonary-based findings (MRvol MPAi) (bias = 9.5 ml; limits of agreement: −11.7–30.7 with a difference of 47 ml in the extreme case). The differences between aortic-based and pulmonary-based MRvol values calculated using LVSV excl mirrored those derived using LVSV incl. However, MRvol values calculated using LVSV excl were lower in all the groups analyzed (HCM with LVOT obstruction, HCM without LVOT obstruction, and controls) and with all methods of MRvol quantification used ( p ≤ 0.0001 for all comparisons).
In HCM patients, LVOT obstruction significantly affects the estimation of aortic flow, leading to its underestimation and, consequently, to higher MRvol values than those obtained with MPA-based MRvol calculations.